Lion Point Capital’s Benitec Biopharma BNTC Stock Holding History

Lion Point Capital’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$830K	Hold	62,000	–	–	3.97%	8
2026 Q1	$660K	Hold	62,000	–	–	3.95%	9
2025 Q4	$835K	Hold	62,000	–	–	4.32%	6
2025 Q3	$870K	Hold	62,000	–	–	4.94%	9
2025 Q2	$725K	Hold	62,000	–	–	4.93%	10
2025 Q1	$807K	Hold	62,000	–	–	5.15%	7
2024 Q4	$783K	Buy	62,000 +23,000	+59%	+$248K	4.1%	10
2024 Q3	$358K	Buy	+39,000	New	+$349K	0.8%	19

Other funds holding BNTC

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Lion Point Capital's BNTC Position: Q2 2026 in Review

Lion Point Capital held its Benitec Biopharma (BNTC) position steady in Q2 2026 at 62,000 shares worth $830K. The position accounts for 3.97% of the portfolio, ranked #8.

Lion Point Capital first reported a position in BNTC in Q3 2024 and has held it in 8 quarters since. The position peaked at $870K in Q3 2025. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

Lion Point Capital held 62,000 shares of Benitec Biopharma worth $830K as of Q2 2026.
Lion Point Capital left its Benitec Biopharma share count unchanged in Q2 2026.
Benitec Biopharma made up 3.97% of Lion Point Capital's portfolio in Q2 2026, its #8 holding.
Lion Point Capital first reported a position in Benitec Biopharma in Q3 2024 and has held it in 8 quarters since.
Lion Point Capital's Benitec Biopharma position peaked at $870K in Q3 2025.
87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Lion Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.